Biotech News

Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026

Lisata Therapeutics (LSTA)Lisata TherapeuticsCompany update

LIBERTY CORNER, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ: LSTA) (“Lisata” or the “Company”) today announced a one-for-fifteen reverse stock split of its common stock. The Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital

Related news

LSTALisata Therapeutics2026-11-05 13:30 EST

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences

LSTALisata Therapeutics2026-11-09 14:00 EST

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine

RLAYRelay Therapeutics2026-11-02 21:05 EST

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

CMPXCompass Therapeutics2026-11-02 14:00 EST

Compass Therapeutics to Participate in Upcoming November Investor Events

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

NRIXNurix Therapeutics2026-11-11 12:00 EST

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer

NRIXNurix Therapeutics2026-11-10 12:00 EST

Nurix Therapeutics to Participate in Upcoming Investor Conferences

CGEMCullinan Therapeutics, Inc.2026-11-09 15:00 EST

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CGEMCullinan Therapeutics, Inc.2026-11-04 14:14 EST

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

FATEFate Therapeutics2026-11-03 21:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Lisata Therapeutics

Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors. Its story is built around the idea that better access to tumors can improve the performance of other anti-cancer approaches.

Recent company news

Stock data

Close
0.91 USD
Market cap
31.69M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States